GU Cancers 2021 | Characterization of PSA responses to bipolar androgen therapy in mCRPC

Emmanuel Antonarakis, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, highlights the molecular and clinical characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who achieve deep prostate-specific antigen (PSA) responses to bipolar androgen therapy (BAT). Next-generation somatic DNA sequencing was obtained on 15 patients with mCRPC who achieved over a 70% PSA response to BAT. 93% were found to have a pathogenic mutation in TP53 and/or a homologous recombination DNA repair (HRD) gene. This data supports the hypothesis that BAT is most effective for DNA repair-deficient mCRPC patients and warrants prospective investigation. This interview took place during the 2021 Genitourinary Cancers Symposium.